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Abstract
Hashimoto’s Thyroiditis (HT) is one of the most common autoimmune diseases (Hiromatsu et al. 2013 p.13). It primarily affects 
the thyroid gland. The thyroid gland influences growth and regulates the body’s metabolism by manipulating hormonal levels. 
Hashimoto’s thyroiditis affects thyroid function through mechanisms that cause the hormone levels to become dysregulated. 
The standard therapy for Hashimoto’s thyroiditis is hormone replacement. This approach helps most patients by regulating their 
thyroid hormones, though there are some individuals who fail treatment. Untreatable patients are plagued with weight gain, sleep 
disturbances, and other symptoms .  Certain factors in thyroid disease may cause various secondary complications including psychi-
atric manifestations . Research into these patients has shown that the removal of the thyroid gland seems to improve their clinical 
condition. Therefore, in the situation when significant symptoms remain after what appears to be adequate medicinal treatment, 
the possibility of surgery should be entertained. This review discusses the pathological underpinnings of Hashimoto’s disease and 
reviews some of the published literature from the past ten years in relation to the treatment of HT .
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Introduction
The thyroid gland is a butterfly-shaped endocrine gland 
found in the lower front portion of the neck. The thy-
roid primarily controls metabolic function. This includes 
hormone production, growth, and bodily maturation. 
Thermoregulation, as well as brain maturation and other 
cognitive functions, are also controlled by the thyroid 
(Drake 2018). Thyroid dysfunction can be due to hyper-
thyroidism, the overproduction of thyroid hormone, or 
hypothyroidism, which is the underproduction of hor-
mones. The most common symptoms of hyperthyroidism 
are weight loss and palpitations, while the most common 
symptoms of hypothyroidism are weight gain and lethargy 
(Guyton, Hall 2006 Pp. 938-940). 
According to the American Thyroid Association (ATA), 
there are approximately twenty-million people in the 
United States who suffer from thyroid disease. Of this 
twenty-million, about fourteen million of them suffer from 
an autoimmune condition known as Hashimoto’s thyroid-
itis (American Thyroid Association, General Information). 
An autoimmune disease develops when the body’s immune 
system begins attacking its own organs or particular pro-
teins. Autoimmune diseases are caused by autoantibod-
ies, which respond to normal organs as foreign invaders. 
Hashimoto’s Thyroiditis occurs when the body attacks 
either the thyroid cells or their product thyroxine.
Hashimoto’s Thyroiditis can develop in patients with 
either a genetic or environmental susceptibility (Pyzik 
et al. 2015). Hiromatsu et al. studied some of the cur-
rent concepts of genetic susceptibility to Hashimoto’s 
Thyroiditis. They noted that, specifically, the concordance 
rate for HT in identical twins (monozygotic) is 55%, while 
in non-identical twins (dizygotic) it is 0%. Moreover, they 
also observed that there is a higher rate of concordance of 
thyroid autoantibodies not associated with Hashimoto’s 
Thyroiditis in monozygotic twins than in dizygotic twins. 
In these siblings, 80% of monozygotic twins had autoanti-
bodies versus 40% in nonidentical twins (Hiromatsu et al. 
2013). This study concluded that genetics is a significant 
factor in HT.
Several genetic loci have also been identified as associ-
ated with Hashimoto’s thyroiditis, most notably multiple 
human leukocyte antigen-DR (HLA-DR) isotopes. HLA-
DR is a lymphocyte surface receptor.  When genetically 
altered it affects what is presented to the T-cells which 
elicits an immunologic response. This response can influ-
ence the selectivity and binding of peptides, which ap-
pears to predispose individuals to the development of 
HT (Hiromatsu et al. 2013). Other immune modulators 
released from the lymphocytes, such as interferon-gamma 
can also instigate the development of HT.
Environmental triggers that affect individuals suscepti-
ble to Hashimoto’s thyroiditis include infections, dietary 
factors, and pregnancy. Although iodine deficiency can 
cause thyroid diseases, excess iodine can induce autoim-
munity by increasing the body’s sensitivity to abnormal 
thyroglobulin. Thyroglobulin is the protein produced by 
the thyroid and is the precursor to the thyroid hormones 
triiodothyronine (T3) and thyroxine (T4).  In the pres-
ence of excess iodine, thyroglobulin can be abnormally 
iodinated.  This can lead to the production of autoanti-
bodies as well as to the toxicity of the thyroid cells and 
hypothyroidism (Hiromatsu et al. 2013).
With all this in mind, the two main autoantibodies 
linked to Hashimoto’s Thyroiditis are anti-thyroglobulin 
and antithyroid peroxidase.  An anti-thyroglobulin anti-
body binds to thyroglobulin which limits availability and 
subsequent release of T3 and T4 thyroid hormones. The 
thyroglobulin directly affects the functional aspect of the 
thyroid and its reduction, or absence contributes to a 
patient’s hypothyroid symptoms. Antithyroid peroxidase, 
on the other hand, targets thyroid follicular cells or thy-
rocytes. The way it does this is by tagging the thyroid 
cells for destruction which can in turn lead to hypothy-
roidism. HT is an insidious disease that can take years 
before becoming clinically significant (Guyon, Hall 2006, 
Pp. 940-943).
Many patients eventually require treatment with thy-
roid hormone replacement. This therapy involves being 
prescribed a bio-identical thyroid hormone medication, 
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such as Levothyroxine also known as Synthroid or Armor 
Thyroid. For most patients, the treatment works well, 
and the symptoms are resolved. There are circumstances 
though where hormone replacement fails and in cases 
like these clinical research has shown that the surgical 
excision of the thyroid or thyroidectomy should be con-
sidered. This potentially works because it reduces the an-
tibody load and the antibody’s potential effects on other 
targets (Goldvog et al. 2019, p. 462). The main objective 
of this paper is to review the possible solutions to treat-
ment-resistant Hashimoto’s thyroiditis disease.
Methods
Data was collected through Touro College’s online li-
brary using several scientific scholarly databases such 
as ProQuest and PubMed databases. The key-phrases 
used were Hashimoto’s Disease, Hashimoto’s thyroid-
itis, thyroidectomy, and autoimmune thyroiditis. Only 
peer-reviewed journals and English language articles were 
analyzed.
Discussion
Autoimmune thyroid disease was first described in 1912 
by the Japanese surgeon Hakaru Hashimoto (Pyzik et al. 
2015). He identified a cohort of patients with lymphoid 
infiltration of the thyroid with associated destruction of 
the thyroid glands which he called “struma lymphomato-
sa” (Hiromatsu et al. 2013). The concept of autoimmune 
diseases was not recognized until the 1950s and even 
currently many of these diseases are not fully understood. 
Hypothyroidism is diagnosed by a thyroid function blood 
test that shows elevated thyroid stimulating hormone 
(TSH) which reflects a reduction in the thyroid’s function 
(Drake 2018). Unlike many other diseases, patients who 
suffer from hypothyroidism do not exhibit symptoms 
over a set timeline. Some patients develop their symp-
toms over days to months, while for others, symptoms 
evolve over years to decades (Lee 2020). In other words, 
hypothyroidism can exist in many states which can range 
from a subclinical harmless state to a significant clinical 
presentation (Chaker et al. 2017). Table 1 shows a flow 
chart on the process of diagnosing the disease.
There is controversy as to when medical professionals 
should start treating patients with clinical hypothyroid-
ism. According to the American Association of Clinical 
Endocrinology (AACE) guidelines, there are a few opin-
ions as to when treatment commences. Treatment gen-
erally relies on the Thyroid Stimulating Hormone (TSH) 
level. TSH responds to feedback inhibition of the pituitary 
gland, the organ which produces TSH. As the levels of thy-
roid hormone increase, the TSH decreases, and as the 
levels of thyroid hormone decrease the TSH increases. 
This is an example of a negative feedback loop (Guyon, 
Hall 2006, p. 939). The American Thyroid Association’s 
guidelines suggest that when the TSH levels approach 10 
mIU/L patients are clinically hypothyroid and need treat-
ment. Others claim that there are therapeutic reasons 
to start treating at lower levels. Regardless, treatment 
is always dependent on the clinical symptoms being ad-
dressed (Garber et al. 2012, p. 1112).
The most common symptoms of hypothyroidism in 
adults are weight gain, fatigue, hot/cold intolerance, and 
memory loss (brain fog). Table 2 lists the signs and symp-
toms related to hypothyroidism. The symptoms for the 
diagnosis of hypothyroidism are reflective of the hormon-
al insufficiency in different organs (Carle et al. 2014, p. 
593). Symptoms vary by age and health status. An increase 
in the severity of symptoms may predict a harsher course 
of hypothyroidism. Clinical symptoms were originally 
used to diagnose hypothyroidism. A variety of outdated 
scoring systems such as the Billewicz score system and 
the Zulewski score system were utilized. With the advent 
of a sensitive blood test for TSH, these systems have been 
phased out and the fluctuation in TSH levels is what is 
used to guide the treatment of the disease.
Thyroid function has also been proven to play a cru-
cial role in the cognitive development of youth and 
many other facets regulating nervous system activity. 
Neuropsychiatric symptoms refer to a gamut of emo-
tional and cognitive complications that are directly re-
lated to alterations in the brain (Dickerman, Barnhill 
2012). Due to the close association between thyroid and 
the nervous system function, disturbances in the body’s Table1: Diagnostic scheme (Chaker et al . 2017)
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metabolic state can be related to a range of neurologi-
cal signs and symptoms. These signs include headaches, 
mood, and cognitive disorders, ophthalmoplegia (eye 
movement disorder), tremors, and muscle weakness. 
Hypothyroidism can cause psychiatric symptoms such as 
depression, anxiety, memory deficits, and even psychosis. 
According to medical guidelines, testing for thyroid dis-
ease is a case-by-case decision, but patients who present 
with psychiatric issues should all be screened for thyroid 
dysfunction (Dickerman, Barnhill 2012, p.130).
In the neuropsychiatric realm, a sudden worsening in a 
patient’s hypothyroidism may result in myxoedema coma, 
a life-threatening condition that is also associated with a 
rapid decline in mental health.  The degree to which sub-
clinical hypothyroidism and mild hypothyroidism impacts 
moods and cognitive functions, as well as whether these 
symptoms respond to treatment, remains controversial 
(Stasiolek 2015).  A case study reported a 61-year-old 
woman who first presented to the emergency room 
complaining of severe chronic daily headaches. According 
to the patient, the headaches started 9 months prior and 
were described as, “bi-lateral with pressing-type quality, 
without associated symptoms such as nausea, photopho-
bia, and did not worsen with exercise,”. The patient also 
presented with depressive symptoms which were evalu-
ated by a psychiatrist. The woman was subsequently diag-
nosed as having depressive syndrome. She was prescribed 
antidepressants but the medication failed to correct the 
problem. The patient later had a full medical evaluation 
which included blood work. The blood work revealed 
an increased anti-TPO antibody titer. This patient was 
diagnosed with encephalopathy related to autoimmune 
thyroid disease, which is also known as Hashimoto’s en-
cephalopathy (Correia et al. 2019).
Another physical ailment associated with hypothyroid-
ism is reduced cardiac output.  This is a result of the re-
laxation of vascular smooth muscle tissue. This relaxation 
occurs because the thyroid hormones which control 
the pacemaker-related genes reduce the heart rate and 
cardiac output which subsequently increases arterial stiff-
ness leading to hypertension. (Udovcic et al. 2017,  p. 55). 
Because of this process, a person’s heart rate will elevate 
in the presence of excess thyroid hormone (hyperthy-
roidism) or reduce if the person has less thyroid hormone 
present (hypothyroidism). The change from normal levels 
to abnormal levels produces a domino effect of increased 
arterial stiffness, which then causes increased systemic 
vascular resistance. A variety of medicinal conditions can 
arise due to these changes which include atrial fibrillation 
and heart failure (Udovcic et al. 2017).
Thyroid dysfunction can also be associated with 
changes in body temperature and body weight. The thy-
roid-stimulating hormone regulates the basal metabolism, 
thermogenesis, and lipid glucose metabolism (Sanyal, 
Raychaudhuri 2016). “According to the National Health 
and Nutrition Examination Survey, obesity affected 32.2% 
of adults in 2003–2004.” (Biondi 2010, p. 3614). A study 
performed in India at the Medwin Hospital’s department 
of Endocrinology and Obesity Clinic found that thyroid 
dysfunction was realized more in individuals that were 
obese. All the patients included in the study underwent 
a physical examination which included, “Height, weight, 
waist circumference, presence of goiter, acanthosis nig-
ricans or peripheral stigmata of dyslipidemia and blood 
pressure measurement,” (Verma et al. 2008). Their study 
consisted of a total of 1075 patients. The study was divid-
ed into two subgroups. One group was made up of 625 
patients who were enrolled in the hypothyroidism clinic, 
and the other group was 450 patients who were enrolled 
in the obesity clinic. Of the patients from the hypothy-
roidism clinic, 44% of them found that their body mass 
index (BMI) was greater than 25 kg/m2 with the typical 
BMI for a healthy person being anywhere between 18.5 
and 24.9 kg/m2. Of the patients from the obesity clinic, 
only 33% had hypothyroidism (Verma et al. 2008). They 
concluded that most people who suffer from hypothy-
roidism have the likelihood of being obese.
Thyroid glands are also prone to develop nodules 
known as goiters.  A goiter refers to an abnormal enlarge-
ment within the thyroid gland. It is important to stress 
that the majority of people that have goiters do not have 
any thyroid gland dysfunction.  People with Hashimoto’s 
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thyroiditis, however, seem to have more nodules than the 
average person. This leads to patients with Hashimoto 
thyroiditis having a slightly higher risk of developing thy-
roid cancer (Fish 2019 p.334). Some researchers say that 
the higher rate for papillary thyroid carcinoma is due to 
the presence of an autoimmune-response, or possibly 
anti-tumor immune response to the immune mediators 
(Graceffa et al. 2019, p.5).
As mentioned previously in this paper, the primary 
treatment for Hashimoto’s disease consists of hormone 
replacement. Hormone replacement aims to balance the 
patient’s biochemical system. While taking out the thyroid 
might prevent an antibody response, if a patient does not 
have a significant quality of life issue, doctors would not 
suggest having a total thyroidectomy (Promberger et al. 
2014, p. 979). There are cases in which a patient is still 
affected by the symptoms of hypothyroidism, even after 
taking the correct dosage of medication and correcting 
the abnormal TSH level.  In that instance, doctors might 
suggest that the patient undergo a total thyroidectomy 
(Pollock et al. 2001, p.894).
There are some standard indications as to when it is 
appropriate to have a thyroidectomy beyond having thy-
roid cancer. When a patient starts to exhibit compressive 
symptoms such as discomfort while swallowing, the feeling 
of strangulation, or tightness in the neck, it is appropriate 
to surgically remove the thyroid gland (Pradeep et al. 2011). 
Greater than 63% of patients with HT identified with the 
symptom of compression (McManus et al. 2011, p. 336). 
Another symptom that hormone replacement cannot cure 
is painful Hashimoto thyroiditis.  Painful HT is also known 
as acute exacerbation of HT.  This condition is not very 
common and in most instances is treated adequately with 
painkillers. Having a total thyroidectomy is thought to be 
the best treatment for this condition especially when pain-
killers do not provide relief (Peng et al. 2020, p.12).
In certain instances, patients with Hashimoto’s disease 
may not necessarily experience a resolution of their com-
plaints with medication. A study of 426 women who were 
all planning on having their thyroids removed for various 
reasons including HT. Before surgery, they all answered 
the SF-36 questionnaire, which is a set of generic, and eas-
ily administered quality-of-life measurements. The results 
established that patients who had high anti-TPO levels 
had lower quality of life measures even though they were 
taking the correct dosage of medication based on their 
TSH levels (Ott et al. 2011, p.165).
In the Annals of Internal Medicine, Guldvog et al., who 
performed the first randomized controlled trial, demon-
strated that the removal of the thyroid gland in patients 
with histologically verified Hashimoto’s disease can 
improve their quality of life by normalizing their anti-TPO 
antibody titer levels. This study was performed on patients 
between the ages of 18 to 79 years. They all had anti-TPO 
titers above 1000 IU/ml (normally less than 35 IU/ml). In 
total there were 150 test subjects all of whom had per-
sistent Hashimoto-related symptoms. Before the data was 
collected and the surgery was performed, all the patients 
were monitored for thyroid function until they achieved 
euthyroid status or normal thyroid function. Participants 
were either assigned to undergo total thyroidectomy with 
continued hormone replacement or to only receive hor-
mone replacement therapy. After 18 months, the anti-TPO 
levels of the surgical group had fallen from a mean of 2232 
IU/ml to 152 IU/ml, and the general health score of the 
surgical group improved from 38 to 64 points. The chronic 
fatigue frequency in the surgical group decreased from 82% 
to 35% of the individuals.  The overall score was improved 
compared to the original SF-36 questionnaire. The control 
group showed no significant changes. The researchers hy-
pothesized that the improvement in symptoms could be 
related to the normalization of serum anti-TPO antibody 
titers. (Goldvog et al. 2019).
Dr. Trevor Angell interpreted and reviewed the study 
done by Guldvog et al. and concluded that the results 
were compelling. Guldvog et al. indicates that patients 
with Hashimoto’s thyroiditis might have persistent symp-
toms due to more than just the thyroid dysfunction. They 
found that a thyroidectomy may modulate the immune 
response by removing the antigen and thereby reducing 
the inflammation and the inflammatory mediators. With 
the removal, the symptoms caused by HT would subse-
quently be alleviated (Angell 2019, p.180).
Nevertheless, the initial plan of treatment for patients 
who have the symptoms of hypothyroidism should be 
supplemental hormone replacement. In the case when 
patients do not respond positively to hormone replace-
ment, a total thyroidectomy has proven to be effective 
as well. For a patient that chooses to have surgery, a 
risk analysis of surgical complications must be evaluated. 
One study predicted that if more people start removing 
their thyroids then complications will increase 12-fold. 
This rate, according to the literature, would change from 
3.05% to 36.6% (Memeh et al. 2020).
Conclusion
In conclusion, not every person who has Hashimoto’s 
thyroiditis should have thyroid surgery. According to the 
research reviewed, having a thyroidectomy might only 
be recommended to patients who have Hashimoto’s 
Thyroiditis and who are experiencing neuropsychiatric 
symptoms after their TSH levels are stabilized. There 
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needs to be more research evaluating and specifying the 
benefits of having a thyroidectomy. Larger test groups 
need to be observed, and the follow-up period should be 
extended. Though they are not frequent, complications of 
total thyroidectomy are real, and the risk-benefit ratio 
must be assessed on a case by case basis.
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